🔎 Trials Near Me

Beranda › Epidermolysis Bullosa Dystrophica › California

Uji klinis Epidermolysis Bullosa Dystrophica di California

7 studi untuk Epidermolysis Bullosa Dystrophica mencari peserta di lokasi di California.

Kota di California

Teks studi resmi (Bahasa Inggris)

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

  • Lucile Packard Children's Hospital, Palo Alto
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06423573

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

  • Lucile Packard Children's Hospital, Palo Alto
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT07700966

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

  • Stanford University, Redwood City
Menerima pesertaFase 1/2
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06834035

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

  • Stanford University School of Medicine, Stanford
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 24 Apr 2026 · NCT01019148

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

  • Mission Dermatology Center, Rancho Santa Margarita
Menerima pesertaFase 3
6 Months · Semua jenis kelamin · Diperbarui 12 Mar 2026 · NCT07016750

MSC EVs in Dystrophic Epidermolysis Bullosa

  • USC /Norris Comprehensive Cancer Center University of Southern California, Los Angeles
Menerima pesertaFase 1/2
6 Months · Semua jenis kelamin · Diperbarui 25 Jun 2025 · NCT04173650

Long-Term Follow-up Protocol

  • Mission Dermatology Center, Rancho Santa Margarita
  • Stanford University, Redwood City
Menerima pesertaStudi observasional
6 Months · Semua jenis kelamin · Diperbarui 8 Jun 2021 · NCT04917887

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.